Results from two multicenter randomized clinical trials showed that advanced NSCLC patients with KEAP1/NFE2L2 mutations had worse clinical outcomes than wild-type patients when treated with immunotherapy and chemotherapy (30). This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.